On Wednesday the 28th Allos announced the results of their randomized phase 2 study comparing Folotyn (pralatrexate; Allos) to Tarceva (erlotinib; Genentech/Roche; OSI) in 201 patients with stage IIIB/V NSCLC who had been previously treated with a platinum containing regimen. The primary endpoint of the trial was overall survival. In the overall patient population a reduction [...]
By David Guy Dendreon On July 1st CMS announced that Dendreon’s Provenge® will undergo a National Coverage Determination (NCD). Quoting CMS: We are opening this national coverage analysis to determine whether or not autologous cellular immunotherapy is reasonable and necessary under sections 1862(a)(1)(A) and/or 1862(a)(1)(E) of the Social Security Act. Although Medicare carriers will cover [...]
OBR green is our dynamic, eco-friendly companion to our print journal Oncology Business Review. Register to begin receiving OBR green today. View the Most Recent Issue»
